K W ter Horst1, P W Gilijamse1, K E Koopman1, B A de Weijer1, M Brands1, R S Kootte2, J A Romijn3, M T Ackermans4, M Nieuwdorp2, M R Soeters1, M J Serlie1. 1. Department of Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands. 2. Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands. 4. Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND/ OBJECTIVES: Insulin resistance is the major contributor to cardiometabolic complications of obesity. We aimed to (1) establish cutoff points for insulin resistance from euglycemic hyperinsulinemic clamps (EHCs), (2) identify insulin-resistant obese subjects and (3) predict insulin resistance from routinely measured variables. SUBJECTS/ METHODS: We assembled data from non-obese (n=112) and obese (n=100) men who underwent two-step EHCs using [6,6-(2)H2]glucose as tracer (insulin infusion dose 20 and 60 mU m(-2) min(-1), respectively). Reference ranges for hepatic and peripheral insulin sensitivity were calculated from healthy non-obese men. Based on these reference values, obese men with preserved insulin sensitivity or insulin resistance were identified. RESULTS: Cutoff points for insulin-mediated suppression of endogenous glucose production (EGP) and insulin-stimulated glucose disappearance rate (Rd) were 46.5% and 37.3 μmol kg(-)(1) min(-)(1), respectively. Most obese men (78%) had EGP suppression within the reference range, whereas only 12% of obese men had Rd within the reference range. Obese men with Rd <37.3 μmol kg(-1) min(-1) did not differ from insulin-sensitive obese men in age, body mass index (BMI), body composition, fasting glucose or cholesterol, but did have higher fasting insulin (110±49 vs 63±29 pmol l(-1), P<0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (4.5±2.2 vs 2.7±1.4, P=0.004). Insulin-resistant obese men could be identified with good sensitivity (80%) and specificity (75%) from fasting insulin >74 pmol l(-1). CONCLUSIONS: Most obese men have hepatic insulin sensitivity within the range of non-obese controls, but below-normal peripheral insulin sensitivity, that is, insulin resistance. Fasting insulin (>74 pmol l(-1) with current insulin immunoassay) may be used for identification of insulin-resistant (or metabolically unhealthy) obese men in research and clinical settings.
BACKGROUND/ OBJECTIVES:Insulin resistance is the major contributor to cardiometabolic complications of obesity. We aimed to (1) establish cutoff points for insulin resistance from euglycemic hyperinsulinemic clamps (EHCs), (2) identify insulin-resistant obese subjects and (3) predict insulin resistance from routinely measured variables. SUBJECTS/ METHODS: We assembled data from non-obese (n=112) and obese (n=100) men who underwent two-step EHCs using [6,6-(2)H2]glucose as tracer (insulin infusion dose 20 and 60 mU m(-2) min(-1), respectively). Reference ranges for hepatic and peripheral insulin sensitivity were calculated from healthy non-obesemen. Based on these reference values, obesemen with preserved insulin sensitivity or insulin resistance were identified. RESULTS: Cutoff points for insulin-mediated suppression of endogenous glucose production (EGP) and insulin-stimulated glucose disappearance rate (Rd) were 46.5% and 37.3 μmol kg(-)(1) min(-)(1), respectively. Most obesemen (78%) had EGP suppression within the reference range, whereas only 12% of obesemen had Rd within the reference range. Obesemen with Rd <37.3 μmol kg(-1) min(-1) did not differ from insulin-sensitive obesemen in age, body mass index (BMI), body composition, fasting glucose or cholesterol, but did have higher fasting insulin (110±49 vs 63±29 pmol l(-1), P<0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (4.5±2.2 vs 2.7±1.4, P=0.004). Insulin-resistant obesemen could be identified with good sensitivity (80%) and specificity (75%) from fasting insulin >74 pmol l(-1). CONCLUSIONS: Most obesemen have hepatic insulin sensitivity within the range of non-obese controls, but below-normal peripheral insulin sensitivity, that is, insulin resistance. Fasting insulin (>74 pmol l(-1) with current insulin immunoassay) may be used for identification of insulin-resistant (or metabolically unhealthy) obesemen in research and clinical settings.
Authors: Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp Journal: Gastroenterology Date: 2012-06-20 Impact factor: 22.682
Authors: Steven E Stern; Ken Williams; Eleuterio Ferrannini; Ralph A DeFronzo; Clifton Bogardus; Michael P Stern Journal: Diabetes Date: 2005-02 Impact factor: 9.461
Authors: M T Ackermans; A M Pereira Arias; P H Bisschop; E Endert; H P Sauerwein; J A Romijn Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Mirjam Langeveld; Karen J M Ghauharali; Hans P Sauerwein; Mariette T Ackermans; Johanna E M Groener; Carla E M Hollak; Johannes M Aerts; Mireille J Serlie Journal: J Clin Endocrinol Metab Date: 2007-12-18 Impact factor: 5.958
Authors: Karin E Koopman; Matthan W A Caan; Aart J Nederveen; Anouk Pels; Mariette T Ackermans; Eric Fliers; Susanne E la Fleur; Mireille J Serlie Journal: Hepatology Date: 2014-05-13 Impact factor: 17.425
Authors: Annie Hasib; Chandani K Hennayake; Deanna P Bracy; Aimée R Bugler-Lamb; Louise Lantier; Faisel Khan; Michael L J Ashford; Rory J McCrimmon; David H Wasserman; Li Kang Journal: Am J Physiol Endocrinol Metab Date: 2019-09-24 Impact factor: 4.310
Authors: R I Versteeg; M T Ackermans; A J Nederveen; E Fliers; M J Serlie; S E la Fleur Journal: Int J Obes (Lond) Date: 2017-08-16 Impact factor: 5.095
Authors: K W Ter Horst; K A van Galen; P W Gilijamse; A V Hartstra; P F de Groot; F M van der Valk; M T Ackermans; M Nieuwdorp; J A Romijn; M J Serlie Journal: Int J Obes (Lond) Date: 2017-05-03 Impact factor: 5.095
Authors: Dov B Ballak; Suzhao Li; Giulio Cavalli; Jonathan L Stahl; Isak W Tengesdal; Janna A van Diepen; Viola Klück; Benjamin Swartzwelter; Tania Azam; Cees J Tack; Rinke Stienstra; Thomas Mandrup-Poulsen; Douglas R Seals; Charles A Dinarello Journal: J Biol Chem Date: 2018-07-13 Impact factor: 5.157
Authors: Francesca Piccinini; David C Polidori; Barbara A Gower; Jose R Fernandez; Richard N Bergman Journal: Diabetes Obes Metab Date: 2018-08-20 Impact factor: 6.577
Authors: Kasper W Ter Horst; Daniel F Vatner; Dongyan Zhang; Gary W Cline; Mariette T Ackermans; Aart J Nederveen; Joanne Verheij; Ahmet Demirkiran; Bart A van Wagensveld; Geesje M Dallinga-Thie; Max Nieuwdorp; Johannes A Romijn; Gerald I Shulman; Mireille J Serlie Journal: Diabetes Care Date: 2020-12-08 Impact factor: 17.152
Authors: Kasper W Ter Horst; Pim W Gilijamse; Barbara A de Weijer; Murat Kilicarslan; Mariette T Ackermans; Aart J Nederveen; Max Nieuwdorp; Johannes A Romijn; Mireille J Serlie Journal: Front Endocrinol (Lausanne) Date: 2015-11-26 Impact factor: 5.555
Authors: Annefleur M Koopen; Eduardo L Almeida; Ilias Attaye; Julia J Witjes; Elena Rampanelli; Soumia Majait; Marleen Kemper; Johannes H M Levels; Alinda W M Schimmel; Hilde Herrema; Torsten P M Scheithauer; Werner Frei; Lars Dragsted; Bolette Hartmann; Jens J Holst; Paul W O'Toole; Albert K Groen; Max Nieuwdorp Journal: Front Microbiol Date: 2021-06-10 Impact factor: 5.640